2018 Section 5 - Rhinology and Allergic Disorders

DURHAM AND PENAGOS

J ALLERGY CLIN IMMUNOL VOLUME 137, NUMBER 2

Dropout rate

Y1:

7.5%

Y2: 17.5%

Y3: 20%

(Continued)

No immunotherapy :

Maintenance group :

Discontinuation group :

Medication scores

357 (0–7,637 [ P 5 .88])

Total medication scores AUC : Year 7

672 (0–1,827)

4,729 (1,197–8,505)

Maintenance group : 921 (0–2,299)

No immunotherapy :

Discontinuation group :

504 (45–4,567 [ P 5 .60])

7 Up to 6 3 3 Total symptom scores AUC : Year 7

2,863 (774–12,033)

blinded after

Years

cessation Symptom scores

after

Years

cessation

therapy

Immuno-

duration (y)

duration (y)

Total

study

SQ-U ; 1,400 m g

Cumulative dose

of Phl p 5

Study methods and immunotherapy schedule Units

continue receiving SCIT (n 5 16) or

3 years 1 (2nd

Maintenance phase: Frequency : Monthly

Build-up phase: Frequency : Twice a week

100,000 SQ-U Duration : 7-8 weeks

Duration : (1st DBPC phase)

(n 5 21) or placebo (n 5 19). After

Dose : 100,000 SQ-U (20 m g of Phl p 5)

receive placebo (n 5 16) for

Dose : From 10 to

Forty patients with severe SAR were randomized to receive SCIT

1 year, patients

receiving placebo

started active SCIT until completing

3 years. Thirty-two

completed the third year. Then, they

were randomized to

DBPC phase) 3 years.

3 years. Fifteen

matched patients with AR were

included as control group (No AIT).

P pratense Study description:

characteristics Allergen

Tests: Positive SPT response to Phleum pratense

Patients’

Diagnosis: Severe SAR associated

with grass pollen

Asthma: Patients with chronic asthma were excluded.

21 19 Age: 19-52 years

country SCIT Placebo

Walker et al, 26

TABLE E2 . (Continued)

Durham et al, 21

and Varney et al, 27 1991,

1995, 1999,

United Kingdom

Author, year,

170